Artificial Intelligence in bone Metastases: A systematic review in guideline adherence of 92 studies
- PMID: 40337637
- PMCID: PMC12056386
- DOI: 10.1016/j.jbo.2025.100682
Artificial Intelligence in bone Metastases: A systematic review in guideline adherence of 92 studies
Abstract
Background: The last decade has witnessed a surge in artificial intelligence (AI). With bone metastases becoming more prevalent, there is an increasing call for personalized treatment options, a domain where AI can greatly contribute. However, integrating AI into clinical settings has proven to be difficult. Therefore, we aimed to provide an overview of AI modalities for treating bone metastases and recommend implementation-worthy models based on TRIPOD, CLAIM, and UPM scores.
Methods: This systematic review included 92 studies on AI models in bone metastases between 2008 and 2024. Using three assessment tools we provided a reliable foundation for recommending AI modalities fit for clinical use (TRIPOD or CLAIM ≥ 70 % and UPM score ≥ 10).
Results: Most models focused on survival prediction (44/92;48%), followed by imaging studies (37/92;40%). Median TRIPOD completeness was 70% (IQR 64-81%), CLAIM completeness was 57% (IQR 48-67%), and UPM score was 7 (IQR 5-9). In total, 10% (9/92) AI modalities were deemed fit for clinical use.
Conclusion: Transparent reporting, utilizing the aforementioned three evaluation tools, is essential for effectively integrating AI models into clinical practice, as currently, only 10% of AI models for bone metastases are deemed fit for clinical use. Such transparency ensures that both patients and clinicians can benefit from clinically useful AI models, potentially enhancing AI-driven personalized cancer treatment.
Keywords: Artificial Intelligence; Guidelines; Machine Learning; Metastatic bone disease; Systematic Review.
© 2025 The Author(s).
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures



Similar articles
-
Development and reporting of artificial intelligence in osteoporosis management.J Bone Miner Res. 2024 Oct 29;39(11):1553-1573. doi: 10.1093/jbmr/zjae131. J Bone Miner Res. 2024. PMID: 39163489 Free PMC article. Review.
-
Adherence to the Checklist for Artificial Intelligence in Medical Imaging (CLAIM): an umbrella review with a comprehensive two-level analysis.Diagn Interv Radiol. 2025 Feb 10. doi: 10.4274/dir.2025.243182. Online ahead of print. Diagn Interv Radiol. 2025. PMID: 39937033
-
Artificial intelligence for breast cancer detection and its health technology assessment: A scoping review.Comput Biol Med. 2025 Jan;184:109391. doi: 10.1016/j.compbiomed.2024.109391. Epub 2024 Nov 22. Comput Biol Med. 2025. PMID: 39579663
-
Artificial Intelligence and Machine Learning in Cancer Related Pain: A Systematic Review.medRxiv [Preprint]. 2023 Dec 8:2023.12.06.23299610. doi: 10.1101/2023.12.06.23299610. medRxiv. 2023. Update in: J Pain Symptom Manage. 2024 Dec;68(6):e462-e490. doi: 10.1016/j.jpainsymman.2024.07.025. PMID: 38105979 Free PMC article. Updated. Preprint.
-
Implementation of Artificial Intelligence in Personalized Prognostic Assessment of Lung Cancer: A Narrative Review.Cancers (Basel). 2024 May 10;16(10):1832. doi: 10.3390/cancers16101832. Cancers (Basel). 2024. PMID: 38791910 Free PMC article. Review.
References
-
- de Groot T.M., Ramsey D., Groot O.Q., Fourman M., Karhade A.V., Twining P.K., Berner E.A., Fenn B.P., Collins A.K., Raskin K., Lozano S., Newman E., Ferrone M., Doornberg J.N., Schwab J.H. Does the SORG Machine-learning Algorithm for Extremity Metastases Generalize to a Contemporary Cohort of Patients? Temporal Validation From 2016 to 2020. Clin Orthop Relat Res. 2023 doi: 10.1097/CORR.0000000000002698. - DOI - PMC - PubMed
-
- Karhade A.V., Groot O., Shah A.A., Bilsky M.H., Laufer I., Park D.Y., Sciubba D.M., Tobert D.G., Bono C.M., Schwab J.H. 61. Development and external validation of predictive algorithms for six-week mortality in spinal metastasis using 4304 patients from five institutions. Spine Journal. 2022;22:S32. doi: 10.1016/j.spinee.2022.06.075. - DOI - PubMed
-
- Karhade A.V., Thio Q.C.B.S., Ogink P.T., Bono C.M., Ferrone M.L., Oh K.S., Saylor P.J., Schoenfeld A.J., Shin J.H., Harris M.B., Schwab J.H. Predicting 90-Day and 1-Year Mortality in Spinal Metastatic Disease: Development and Internal Validation. Neurosurgery. 2019;85:E671–E681. doi: 10.1093/neuros/nyz070. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous